Alpha-cobratoxin as a possible therapy for multiple sclerosis: A review of the literature leading to its development for this application

Critical Reviews in Immunology

Volumn 27, Issue 4, 2007, Pages 291-302

  Reid, Paul F ^a  

^a ReceptoPharm Inc   (United States)

Author keywords

Antiviral; Autoimmune; Myelin; Neurological; Neurotoxin; Nicotinic; Receptor

Indexed keywords

4 AMINOPYRIDINE; ANCROD; BATROXOBIN; BETA1A INTERFERON; CAPTOPRIL; CARDIOTOXIN; COBROTOXIN; CONOTOXIN; CROTOXIN; DISINTEGRIN; ESCOZUL; FRAMPRIDINE; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; MARIMASTAT; MITOXANTRONE; NATALIZUMAB; OMEGA CONOTOXIN MVIIA; PEPTERON; SCORPION VENOM; SNAKE VENOM; SOLUBLE CD4 ANTIGEN; THYMOPENTIN; TIROFIBAN; UNCLASSIFIED DRUG; XIMELAGATRAN; ZICONITIDE;

AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; BLEEDING; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DEPENDENCE; ENCEPHALOMYELITIS; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEOPLASM; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SNAKE; STROKE; SURVIVAL RATE; TOXIN ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; COBRA NEUROTOXIN PROTEINS; COBRA VENOMS; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RECEPTORS, NICOTINIC;

EID: 38049050658     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2(4):201-11.
2. DeGirolami U, Frosch MP, Anthony DC. Pathologic basis of disease. 5th ed. Cotran RS, Kumar V, Robbins SL, editors. Philadelphia: W. B. Saunders; 1994. p. 174-208.
3. Netter FH, The CIBA collection of medical illustrations: nervous system. Vol I. Summit (NJ): CIBA; 1986. p. 174-80.
4. Haahr S, Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol. 2006;16(5):297-310.
5. Cermelli C, Jacobson S. Viruses and multiple sclerosis. Viral Immunol. 2000;13(3):255-67.
6. De Villiers JN, Treurnicht FK, Warnich L, Carr J, van Rensburg SJ, Kotze MJ. Analysis of viral and genetic factors in South African patients with multiple sclerosis. Metab Brain Dis. 2006;21(2-3):163-9.
7. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci U S A. 1997;94(14):7583-8.
8. Haahr S, Sommerlund M, Christensen T, Jensen AW, Hansen HJ, Moller-Larsen A. A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann NY Acad Sci. 1994;724:148-56.
9. Sheldon H, Boyd's introduction to the study of disease. 11th ed. Philadelphia: Lea and Febiger; 1992. p. 517-49.
10. Cavaletti G. Current status and future prospective of immunointervention in multiple sclerosis.Curr Med Chem. 2006;13(19):2329-43.
11. Eisen A, Yufe R, Rop D, Campbell I. Reduced neuromuscular transmission safety factor in multiple sclerosis. Neurology. 1978;28(6):598-602.
12. Trapp BD, Peterson, J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Eng J Med. 1998;338:278-85.
13. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59(3):478-89.
14. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005;233(1-2):3-13.
15. Garrido R, Mattson MP, Hennig B, Toborek M. Nicotine protects against arachidonic acid-induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. Neurochem. 2001;76(5):1395-403.
16. Garrido R, Springer JE, Hennig B, Toborek M. Apoptosis of spinal cord neurons by preventing depletion nicotine attenuates arachidonic acid-induced neurotrophic factors. Neurotrauma. 2003;20(11):1201-13.
17. Garrido R, King-Pospisil K, Son KW, Hennig B, Toborek M, Nicotine upregulates nerve growth factor expression and prevents apoptosis of cultured spinal cord neurons. Neurosci Res. 2003;47(3):349-55.
18. Biala G, Budzynska B, Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol Rep. 2005;57(6):755-60.
19. Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol. 1992;49(12):1243-7.
20. Raine CS. Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest. 1984;50(6):608-35.
21. Fritz RB, Chou CH, McFarlin DE. Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J Immunol. 1983;130(3):1024-6.
22. Trotter JL, Clark HB, Collins KG, Wegeschiede CL, Scarpellini JD. Myelin proteolipid protein induces demyelinating disease in mice. J Neurol Sci. 1987;79(1-2):173-88.
23. Macht DI. Experimental and clinical study of cobra venom as an analgesic. Proc Natl Acad Sci USA. 1936;22(1):61-71.
24. Van Esveld LW. Preparation of "Cobratoxin" for clinical purposes, especially for the treatment of cancer pains. Biochem Zeitschrift 1936;283:343-57.
25. Hills RG, Firor WM. The use of more potent cobra venom for intractable pain. Am Surg. 1952;18(9):875-9.
26. Taren JA. A clinical evaluation of cobra venom extracts for control of pain. Med Bull (Ann Arbor). 1953;19(8):206-11.
27. Grasset E., The cobra neurotoxin; pharmacology and clinical applications in the treatment of pain. Med Hyg (Geneve). 1952;10(212):55-8.
28. Bryson KD. The treatment of chronic arthritis with a combination of cobra venom, formic acid, and silicic acid. Am Surg. 1954;20(7):751-5.
29. Williams EY. Treatment of trigeminal neuralgia with cobra venom. J Natl Med Assoc. 1960;52:327-8.
30. Singh I, Srivastava MC. Anti-asthmatic effects of immunization with cobra venom. Br J Dis Chest. 1968;62(2):107-9.
31. Oaks LW, Quinn JH., Cobra venom in ocular therapy. Trans Pac Coast Otoophthalmol Soc Annu Meet. 1954;35:71-82.
32. Jackman AI. Cobra venom therapy in the neuroses; a preliminary report. Dis Nerv Syst. 1954;15(4):99-102.
33. Wang S, He Y, Peng S. Preparation of venom and its analgesic activity. Zhongcaoyo. 1986;17(1): 7-9.
34. Meiselas LE, Schlecker AA. The effect of nyloxin on the pain of arthritis. NY State J Med. 1957;57(12):2067-8.
35. Lamb G, Hunter W. On the action of venoms of different species of poisonous snakes on the nervous system. Lancet. 1904;1:20.
36. Sanders M, Soret MG, Akin B. Neurotoxoid interference with two human strains of poliomyelitis in rhesus monkeys. Ann NY Acad Sci. 1953;58:1-12.
37. Sanders M, Soret MG, Akin B. Naja Flava neurotoxoid interference late in experimental poliomyelitis, J Path Bact. 1954;68:1267.
38. Sanders M, Soret MG, Akin BA, Roizin L. Neurotoxoid interference in Macacus rhesus infected intramuscularly with poliovirus. Science. 1958;127:594-6.
39. Clark WB, Baldone JA, Thomas CI. The use of sanders neurotoxoid i (modified snake venom) in the treatment of recurrent herpes simplex of the cornea: progress report. South Med J. 1962;55( 9):947-51.
40. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. JAMA. 1953;151(13):1081-98.
41. Sabin AB. Behavior of chimpanzee avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci. 1955;230(1):1-8.
42. Sanders M, Fellowes ON. Use of detoxified snake neurotoxin as a partial treatment for amyotrophic lateral sclerosis. Cancer Cytol. 1975;15:26-30.
43. Tyler HR. Double-blind study of modified neurotoxin in motor neuron disease. Neurology. 1979;29:77-81.
44. Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Arch Neurol. 1979;37:201-3.
45. Mulder DW, Howard FM. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc. 1976;51(9):537-41.
46. Miller KD, Miller GG, Sanders M, Fellowes O. Inhibition of virus-induced plaque formation by atoxic derivatives of purified cobra neurotoxins. Biochim Biophys Acta. 1977;496:192-6.
47. Lentz TC, Wilson M. Neurotoxin-binding site on the acetylcholine receptor. Int Rev Neurobiol. 1988;29:117-60.
48. Lukas RJ. Diversity and patterns of regulation of nicotinic receptor subtypes. Ann NY Acad Sci. 1995;757:153-168.
49. Colquhoun LM, Patrick JW. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmac. 1997;39:191-220.
50. Sargent PB, Pang DZ. Denervation alters the size, number and distribution of clusters of acetylcholine receptor-like molecules on frog cardiac ganglion neurons. Neuron. 1988;1:866-77.
51. Quik M, Geertsen S, Trifaro JM. Marked up-regulation of the beta-bungarotoxin site in adrenal chromaffin cells by specific nicotinic antagonists, Mol Pharmacol. 1987;3(1):385-91.
52. Schultz DW, Zigmond RE. Neuronal bungarotoxin blocks the nicotinic stimulation of endogenous dopamine release from rat striatum. Neurosci Lett. 1989;98:310-16.
53. Lena C, Changeux JP. Role of Ca2+ ions in nicotinic facilitation of GABA release in mouse thalamus, J Neurosci. 1997;17:576-85.
54. Marx A, Kirckner T, Hoppe F, O'Connor R, Schalke B, Tzartos S, Muller-Hermelink HK. Proteins with epitopes of the acetylcholine receptor in epithelial cell cultures of thymomas in myasthenia gravis. Am J Pathol. 1989;34(4):65-75.
55. Richman DP, Arnason BG. Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci USA. 1979;76(9):4632-5.
56. Nelson S, Conti-Tronconi BM. Adult thymus expresses an embryonic nicotinic acetylcholine receptor-like protein. J Neuroimmunol. 1990;29:81-92.
57. Placzek R, Krassnigg F, Schill WB. Effect of ace-inhibitors, calmodulin antagonists, acetylcholine receptor blocking, and alpha receptor blocking agents on motility of human sperm. Arch Androl. 1988;21:1-10.
58. Baccetti B, Burrini AG, Collodel G, Falugi C, Moretti E, Piomboni P. Localisation of two classes of acetylcholine receptor-like molecules in sperms of different animal species. Zygote. 1995;3:207-17.
59. Lentz TC, Hawrot E, Wilson M. Synthetic peptides corresponding to sequences of snake venom neurotoxins and rabies virus glycoprotein bind to the nicotinic acetylcholine receptor: proteins: structure, function and genetics. 1987;2:298-307.
60. Neri P, Bracci L, Rustici M, Santucci A. Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins. Is the nicotinic acetylcholine receptor an HIV receptor? Arch Virol. 1990;114:265-69.
61. Lalo U, Pankratov Y, Krishtal O, North RA. Methyllycaconitine, alpha-bungarotoxin and (+)-tubocurarine block fast ATP-gated currents in rat dorsal root ganglion cells. Br J Pharmacol. 2004;142(8):1227-32.
62. Karlsson E, Eaker D, Drevin H. Modification of the invariant tryptophan residue of two naja naja neurotoxins. Biochim Biophys Acta. 1973;328:510-9.
63. Hudson RA, Montgomery IN, Rauch HC. Experimental allergic encephalomyelitis: prevention with a nontoxic derivative of a cobra neurotoxin. Mol Immunol. 1983;20(2):229-32.
64. Martin BM, Chibber BA, Maelicke A. The sites of neurotoxicity in a-cobratoxin. J Biol Chem. 1983;258(14):8714-22.
65. Chang CC, Kawata Y, Sakiyama F, Hayashi K. The role of an invariant tryptophan reside in alpha-bungarotoxin and cobrotoxin. Investigation of active derivatives with the invariant tryptophan replaced by kynurenine. Eur J Biochem, 1990;193:567-72.
66. Lin SR., Chi SH., Chang LS, Kuo KW, Chang CC. Chemical modification of cationic residues in toxin a from king cobra (ophiophagus hannah) venom. J Protein Chem. 1996;15:95-101.
67. Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res. 2006;28(3):291-8.
68. Sanders M, Porcello JA, Fellowes ON, Lenox AC. The use of modified neurotoxin in amyotrophic lateral sclerosis. Phi Lambda Kappa - MSAS Annual Scientific Session. March, 1977.
69. Gallagher JP, Sanders M. Apparent motor neuron disease following the use of pneumatic tools. Anal Neurol. 1983;14(6):694-5.
70. Yourist JE, Haines HG, Miller KD. Inhibition of herpes simplex virus replication by cobra a-neurotoxin. J Gen Virol. 1983;64:1475-81.
71. Zhang HL, Han R, Chen ZX, Gu ZL, Reid PF, Raymond LN, Qin ZH. Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom. Neurosci Bull. 2006;22(5):267-73.
72. Miller K, Porter R, Miller G, Miale A. Pharmacokinetics employing 99m-Pertechnetate [Abstract of the Sixth Annual Meeting of the Southeastern Pharmacology Society]. J Clin Pharm. 1985;25:633.
73. Vargas F, Cortes M. Primera experiencia en el tratamiento de infecciones herpeticas con neuevo antiviral (peptido-E o immunoquina). Rev Chil Urol. 1995;60:242-6 (in Spanish).
74. Mundy HR, Jones SJ, Hobart JC, Hanna MG, Lee PJ, A randomized controlled trial of modified cobratoxin in adrenomyeloneuropathy. Neurology. 2003;61:528-30.
75. Sanders M , Soret MG, Akin BA. Neurotoxoid interference principle in pseudorabies infection, in vivo inactivation of Aujeszky virus. Proceedings of the 7th International Congress of Microbiology; Stockholm, Sweden; 1958. p. 299.
76. Patterson B, Flener Z, Yogev R, Kabat W. Inhibition of HIV-1 replication in mononuclear cells and thymus explant cultures by a purified, detoxified cobra venom protein. Abstract. Novel biological fusion inhibitors of HIV; 2000 April 7; Keystone Conference; Colorado.
77. Fazakerley JK, Walker R. Virus demyelination. J Neurovirol. 2003;9(2):148-6.
78. Castaneda-Castellanos DR, Castellanos JE, Hurtado H. Differential use of the nicotinic receptor by rabies virus based upon substrate origin. J Neurovirol. 2002;8(2):150-4.
79. Hinman CL, Stevens-Truss R, Schwarz C, Hudson RA. Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action. Immunopharmacol Immunotoxicol. 1999;21(3):483-506.
80. Mohamed A, Reid PF, Raymond L, Dufan T. Amelioration of acute and relapsing stages of the experimental allergic encephalomyelitis by cobra toxins. Biomed Sci Instrum. 2006;42:399-404.
81. Montsdeoca G, Stoik R. Human clinical trials on the effect of Pepteron in rheumatoid arthritis. SE Sect, Vol 10. Charleston, SC: Soc Exp Biol Med; 1985.
82. Mizuno Y, Dosch HM, Gelfand EW. Carbamycholine modulation of E-rosette formation: identification of nicotinic acetylcholine receptors on a subpopulation of human T lymphocytes. J Clin Immunol. 1982;2(4):303-8.
83. Dargent B, Arsac C, Tricaud N, Couraud F. Activation of voltage-dependent sodium channels in cultured cerebellar poffule cells induces neurotoxicity that is not mediated by glutamate release. Neuroscience. 1996;73(1):209-16.
84. Umemura K, Gemba T, Mizuno A, Nakashima M. Inhibitory effect of MS-153 on elevated brain glutamate level induced by rat middle cerebral artery occlusion. Stroke. 1996;27:1624-8.
85. Carlson NG, Bacchi A, Rogers SW, Gahring LC. Nicotine blocks TNF-alpha-mediated neuroprotection to NMDA by an alpha-bungarotoxin-sensitive pathway. J Neurobiol. 1998;35(1):29-36.
86. Pittman R, Oppenheim RW. Cell death of motoneurons in the chick embryo spinal cord. IV. Evidence that a functional neuromuscular interaction is involved in the regulation of naturally occurring cell death and the stabilization of synapses. J Comp Neurol. 1979;187(2):425-46.
87. Renshaw G, Rigby P, Self G, Lamb A, Goldie R. Exogenously administered alpha-bungarotoxin binds to embryonic chick spinal cord: implications for the toxin-induced arrest of naturally occurring motoneuron death. Neuroscience. 1993;53:1163-72.
88. Renshaw GM. [125I]-alpha-bungarotoxin binding covaries with motoneurone density during apoptosis. Neuroreport. 1994;5(15):1949-52.
89. Hory-Lee F, Frank E, The nicotinic blocking agents d-tubocurare and a-bungarotoxin save motoneurons from naturally occurring death in the absence of neuromuscular blockade. J Neurosci. 1995;15(10):6453-60.
90. Oppenheim RW, Bursztajn S, Prevette D. Cell death of motoneurons in the chick embryo spinal cord. XI. Acetylcholine receptors and synaptogenesis in skeletal muscle following the reduction of motoneuron death by neuromuscular blockade. Development. 1989;107(2):331-41.
91. Oppenheim RW, Prevette D, D'Costa A, Wang S, Houenou LJ, McIntosh JM. Reduction of neuromuscular activity is required for the rescue of motoneurons from naturally occurring cell death by nicotinic-blocking agents. J Neurosci. 2000;20(16):6117-24.
92. Stiles BG. A non-radioactive receptor assay for snake venom postsynaptic neurotoxins. Toxicon. 1991;29:503-10.
93. Chen ZX, Zhang HL, Gu ZL, Chen BW, Han R, Reid PF, Raymond L, Qin ZH. A long-form α-neurotoxin from cobra venom produces potent opioid-independent analgesia. Acta Pharmacol Sinica. 2006;27(4):402-8.
94. Tseng LF, Chiu TH, Lee CY. Absorption and distribution of i-labeled cobra venom and its purified toxins. Toxicol Appl Pharmacol. 1968;12:526-35.
95. Henze T., Managing specific symptoms in people with multiple sclerosis. Int MS J. 2005;12(2):60-8.
96. Chen R, Robinson SE. Effect of cholinergic manipulations on the analgesic response to Cobrotoxin in mice. Life Sci. 1990;47:1949-54.
97. Xu JM, Song ST, Yu CZ, Yang Y, Cui M, Wang WU, Xiong YL, Paradiso A randomized, double-blind, placebo-controlled, parallel multicenter trial of Cobrotoxin-containing compound analgesic in the treatment of postoperative pain. Europain. 2002;2(2) [Abstract].
98. Xu JM, Song ST, Feng FY, Huang FL, Yang Y, Xie GR, Xu LG, Paradiso A. Compound Keluoqu for treatment of chronic moderate to severe cancer pain: a multicenter randomized trial. 2002 ASCO Annual Meeting. Abstract No. 1762.
99. Heininger K, Fierz W, Schafer B, Hartung HP, Wehling P, Toyka KV. Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat. Brain. 1989;112( Pt 2):537-52.
100. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Beraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA. 2001;98(24):13942-7.
101. Skerl V, Pavlovic M. Thymopoietins and long postsynaptic neurotoxins share common information in their primary structures. FEBS Lett. 1988;239(1):141-6.
102. Thrower PA, Doyle DV, Scott J, Huskisson EC. Thymopoietin in rheumatoid arthritis. Rheumatol Rehabil. 1982;21(2):72-7.
103. Sundal E, Bertelletti D. Management of viral infections with thymopentin. Arzneimittelforschung. 1994;44(7):866-71. Review.
104. Cognazzo A, Seliak D, Fruttero A. Effect of thymopentin on peripheral blood T-lymphocytes subsets and on the clinical course of the disease in patients affected by multiple sclerosis. Rev Neurol. 1991;61(3):110-5.
105. Borromei A, Draghetti M, Guerra L, Lozito A, Vargiu B. Multiple sclerosis: a report of a case treated with thymopentin. Minerva Med. 1995;86(5):227-32.
106. Friedmann N. Thymopentin: safety overview. Surv Immunol Res. 1985;4(Suppl 1):139-48.
107. Ochoa EL, Li LA, Plummer A, McNamee MG. Direct effects of thymopentin (Arg-Lys-Asp-Val-Tyr) on cholinergic agonist-induced slow inactivation of nicotinic acetylcholine receptor function. Mol Pharmacol. 1990;38(6):863-71.